# Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma

> **NCT02258555** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 7 (actual)

## Conditions studied

- Follicular Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** GS-9901

## Key facts

- **NCT ID:** NCT02258555
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2015-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02258555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02258555, "Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02258555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*